News
The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.
Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...
ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution. The Food and Drug Administration (FDA) has accepted for review ...
To assess the safety and efficacy of IV ibuprofen in older adults, researchers conducted a post hoc subgroup analysis with data from 4 prospective clinical studies.
Statins recommended for persons with HIV with a 10-year ASCVD risk score of 5 percent or higher; favored for those with risk score ...
“Banning NIH-funded researchers from publishing in leading medical journals and requiring them to publish only in journals that carry the RFK Jr. seal of approval would delegitimize taxpayer-funded ...
Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...
In a recent interview on NBC News’ "Meet the Press," Murthy said Congress has failed to act on what he described as a growing crisis.
Nucala gains new indication; FDA implements stricter guidance for COVID-19 vaccine approval; pruritus reported following discontinuation of long-term antihistamines; antibiotic looks promising for ...
The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...
The protest happened roughly 27 minutes into the meeting, held at NIH headquarters in Bethesda, Md. In a video obtained by CNN, Bhattacharya is shown telling staff that, based on his review of ...
The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results